JP2020529847A5 - - Google Patents

Download PDF

Info

Publication number
JP2020529847A5
JP2020529847A5 JP2020505464A JP2020505464A JP2020529847A5 JP 2020529847 A5 JP2020529847 A5 JP 2020529847A5 JP 2020505464 A JP2020505464 A JP 2020505464A JP 2020505464 A JP2020505464 A JP 2020505464A JP 2020529847 A5 JP2020529847 A5 JP 2020529847A5
Authority
JP
Japan
Prior art keywords
cancer
immune cells
types
cells
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020505464A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529847A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/044740 external-priority patent/WO2019028098A1/en
Publication of JP2020529847A publication Critical patent/JP2020529847A/ja
Publication of JP2020529847A5 publication Critical patent/JP2020529847A5/ja
Pending legal-status Critical Current

Links

JP2020505464A 2017-08-03 2018-08-01 がんの処置のための方法および組成物 Pending JP2020529847A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762540901P 2017-08-03 2017-08-03
US62/540,901 2017-08-03
PCT/US2018/044740 WO2019028098A1 (en) 2017-08-03 2018-08-01 METHODS AND COMPOSITIONS FOR TREATING CANCER

Publications (2)

Publication Number Publication Date
JP2020529847A JP2020529847A (ja) 2020-10-15
JP2020529847A5 true JP2020529847A5 (https=) 2021-09-09

Family

ID=65234162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020505464A Pending JP2020529847A (ja) 2017-08-03 2018-08-01 がんの処置のための方法および組成物

Country Status (10)

Country Link
US (1) US20200155600A1 (https=)
EP (1) EP3661953A4 (https=)
JP (1) JP2020529847A (https=)
KR (1) KR20200036874A (https=)
CN (1) CN111094328A (https=)
AU (1) AU2018308982A1 (https=)
CA (1) CA3071448A1 (https=)
IL (1) IL272147A (https=)
SG (1) SG11202000724XA (https=)
WO (1) WO2019028098A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113874033A (zh) * 2019-04-08 2021-12-31 泰加生物工艺学公司 用于冷冻保存免疫细胞的组合物和方法
EP3969041A4 (en) * 2019-05-14 2023-05-10 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358739B1 (en) * 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
US20040241140A1 (en) * 2000-11-01 2004-12-02 Pavlakis George N. Expression vectors able to elicit improved immune response and methods of using same
US20030216315A1 (en) * 2002-02-13 2003-11-20 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
WO2005084158A2 (en) * 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
IL296832A (en) * 2005-10-18 2022-11-01 Nat Jewish Health Process of preparing red blood cells using conditionally immortalized long-term hematopoietic stem cells and erythropoietin
DK3339321T3 (da) * 2008-08-28 2021-06-21 Taiga Biotechnologies Inc Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc
US9789135B2 (en) * 2012-07-20 2017-10-17 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US9365825B2 (en) * 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
DK2986311T3 (en) * 2013-04-18 2019-02-25 Tilt Biotherapeutics Oy IMPROVED ADOPTIVE CELL THERAPY
ES2905757T3 (es) * 2017-08-03 2022-04-12 Taiga Biotechnologies Inc Métodos y composiciones para el tratamiento del melanoma
US10149898B2 (en) * 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma

Similar Documents

Publication Publication Date Title
Sun et al. Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells
US20220098300A1 (en) Anti trbc1 antigen binding domains
Kiesgen et al. Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies
JP2021058197A5 (https=)
CN118546960A (zh) Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
US11970545B2 (en) T cell-antigen coupler with Y182T mutation and methods of uses thereof
WO2021048724A1 (en) Combined expression of a chimeric cd3 fusion protein and an anti-cd3-based bispecific t cell activating element
Franks et al. New anticancer immunotherapies
JP2020516681A5 (https=)
JP2022512541A5 (https=)
JP2019515653A5 (https=)
IL301995A (en) Cells comprising t cell-antigen couplers and uses thereof
JP2021512637A5 (https=)
JP2021525068A5 (https=)
JP2020529847A5 (https=)
Long et al. HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice
CN115023237A (zh) 癌症或肿瘤的治疗方法
JP2022506781A5 (https=)
WO2022033483A1 (zh) 多功能的免疫效应细胞及其应用
JP2022547809A5 (https=)
WO2023283361A1 (en) Gpc3 t cell-antigen couplers and uses thereof
Snook et al. GUCY2C-targeted cancer immunotherapy: past, present and future
JP2024535781A (ja) 抗原結合タンパク質およびその使用
US12479903B2 (en) CD5 specific T cell receptor cell or gene therapy
JP2022503621A5 (https=)